After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. Inobrodib works by targeting twin cancer proteins p300 and CBP, which impacts the expression of cancer drivers including MYC and IRF4.
52 
Let's personalize your content